Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boehringer, Micromet Enter Antibody Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Boehringer, Micromet Enter Antibody Pact

Boehringer Ingelheim and Micromet, Inc. have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim and Micromet, Inc. have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

Micromet will be responsible for discovery of the BiTE antibody and the two companies will jointly conduct further preclinical studies. BI will be responsible for all manufacturing activities, clinical development and worldwide commercialization subject to Micromet’s co-promotion right in the U.S. Micromet will be responsible for the costs to a pre-defined amount for its preclinical activities. Upon commercialization, Micromet will cover the costs for its sales force in the U.S. BI will cover all other costs for research, development, manufacturing and commercialization of the BiTE antibody.

Under the terms of the agreement, Micromet will receive an upfront cash payment of $5 million. Micromet is also eligible to receive development and regulatory milestone payments of as much as $66 million and royalties on product sales outside the U.S. In the U.S. the two companies will jointly promote the BiTE antibody.

“Multiple myeloma will be an indication of focus for Micromet and we are very pleased to collaborate with Boehringer Ingelheim, an industry leader with a proven track record of successful partnerships,” said Christian Itin, Ph.D., Micromet’s president and chief executive officer. “In line with the strategic importance of hemato-oncology for Micromet we have retained U.S. co-promotion rights for this product candidate consistent with our goal of building a commercial hematology franchise in the United States.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters